Hiberix Disease Interactions
There are 2 disease interactions with Hiberix (haemophilus b conjugate (prp-t) vaccine).
Vaccines (applies to Hiberix) IM injection
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Thrombocytopathy, Coagulation Defect
In patients with thrombocytopenia or coagulation disorders, IM injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine; hepatitis A and B vaccines; aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered IM. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.
Vaccines (live attenuated/toxoid) (applies to Hiberix) immunocompromised
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.
Hiberix drug interactions
There are 289 drug interactions with Hiberix (haemophilus b conjugate (prp-t) vaccine).
More about Hiberix (haemophilus b conjugate (prp-t) vaccine)
- Hiberix consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bacterial vaccines
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.